series-c-plus
Stage
2014
Founded
1
Investors
About
Inotrem is a clinical-stage biotechnology company developing first-in-class immunotherapies. They focus on modulating the TREM-1 pathway to treat acute and chronic inflammatory diseases.
Explore Inotrem's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.